

Francisco Cruz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9360540/francisco-cruz-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

5,168
citations

41
h-index

66
g-index

231
ext. papers

5,920
ext. citations

4.4
avg, IF

5.6
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 162 | Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. <i>European Urology</i> , 2011 , 60, 742-50 | 10.2 | 332 |
| 161 | Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. <i>Journal of Neuroscience</i> , 2004 , 24, 11253-63 | 6.6 | 164 |
| 160 | EAU guidelines on surgical treatment of urinary incontinence. <i>European Urology</i> , 2012 , 62, 1118-29 | 10.2 | 160 |
| 159 | EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. <i>European Urology</i> , 2018 , 73, 596-609 | 10.2 | 146 |
| 158 | EAU guidelines on assessment and nonsurgical management of urinary incontinence. <i>European Urology</i> , 2012 , 62, 1130-42 | 10.2 | 146 |
| 157 | Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , 2009 , 19, 380-94 | 2.8 | 143 |
| 156 | Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. <i>European Urology</i> , 2010 , 58, 360-5 | 10.2 | 141 |
| 155 | TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006 , 373, 287-99 | 3.4 | 141 |
| 154 | TRPV1: a therapeutic target for novel analgesic drugs?. <i>Trends in Molecular Medicine</i> , 2006 , 12, 545-54 | 11.5 | 136 |
| 153 | The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. <i>Journal of Urology</i> , 2002 , 168, 575-579 | 2.5 | 130 |
| 152 | Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. <i>European Urology</i> , 2017 , 72, 424-431 | 10.2 | 114 |
| 151 | Desensitization of Bladder Sensory Fibers by Intravesical Capsaicin has Long Lasting Clinical and Urodynamic Effects in Patients With Hyperactive or Hypersensitive Bladder Dysfunction. <i>Journal of Urology</i> , 1997 , 157, 585-589 | 2.5 | 109 |
| 150 | Pregnancy and Cholelithiasis: Pathogenesis and Natural Course of Gallstones Diagnosed in Early Puerperium. <i>Hepatology</i> , 1993 , 17, 1-4 | 11.2 | 103 |
| 149 | Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. <i>Journal of Urology</i> , 2007 , 177, 1537-41 | 2.5 | 95 |
| 148 | GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. <i>Journal of Urology</i> , 2009 , 181, 379-86 | 2.5 | 78 |
| 147 | Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. <i>European Urology</i> , 2010 , 57, 884-90 | 10.2 | 70 |
| 146 | Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. <i>Pain</i> , 2005 , 116, 411-419 | 8 | 69 |

| | | | |
|-----|--|------|----|
| 145 | Vanilloid receptor and detrusor instability. <i>Urology</i> , 2002 , 59, 51-60 | 1.6 | 65 |
| 144 | Neurotrophins as regulators of urinary bladder function. <i>Nature Reviews Urology</i> , 2012 , 9, 628-37 | 5.5 | 64 |
| 143 | Mechanisms involved in new therapies for overactive bladder. <i>Urology</i> , 2004 , 63, 65-73 | 1.6 | 64 |
| 142 | The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. <i>Current Neuropharmacology</i> , 2007 , 5, 244-52 | 7.6 | 61 |
| 141 | Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. <i>BJU International</i> , 2009 , 103, 500-4 | 5.6 | 60 |
| 140 | Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. <i>European Urology</i> , 2008 , 53, 153-9 | 10.2 | 59 |
| 139 | Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2007 , 26, 920-7 | 2.3 | 59 |
| 138 | Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. <i>Journal of Urology</i> , 2013 , 189, 548-53 | 2.5 | 58 |
| 137 | Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. <i>European Urology</i> , 2012 , 61, 1178-84 | 10.2 | 57 |
| 136 | OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. <i>Advances in Therapy</i> , 2013 , 30, 819-33 | 4.1 | 57 |
| 135 | Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. <i>Journal of Urology</i> , 2009 , 182, 2944-50 | 2.5 | 56 |
| 134 | Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desensitization by capsaicin or resiniferatoxin. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2000 , 86, 37-46 | 2.4 | 56 |
| 133 | Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. <i>Journal of Urology</i> , 2013 , 189, 359-65 | 2.5 | 55 |
| 132 | Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: results at 12-month follow-up. <i>European Urology</i> , 2011 , 59, 940-4 | 10.2 | 55 |
| 131 | Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. <i>BJU International</i> , 2004 , 94, 153-7 | 5.6 | 54 |
| 130 | Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. <i>European Journal of Neuroscience</i> , 2005 , 21, 773-81 | 3.5 | 53 |
| 129 | Targets for botulinum toxin in the lower urinary tract. <i>Neurourology and Urodynamics</i> , 2014 , 33, 31-8 | 2.3 | 49 |
| 128 | Bladder function after radical hysterectomy for cervical cancer. <i>Neurourology and Urodynamics</i> , 2015 , 34, 309-15 | 2.3 | 48 |

| | | | |
|-----|--|------|----|
| 127 | Spinal cord injury and bladder dysfunction: new ideas about an old problem. <i>Scientific World Journal, The</i> , 2011 , 11, 214-34 | 2.2 | 48 |
| 126 | Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. <i>European Urology</i> , 2005 , 48, 650-5 | 10.2 | 48 |
| 125 | Biomarkers in overactive bladder: a new objective and noninvasive tool?. <i>Advances in Urology</i> , 2011 , 2011, 382431 | 1.6 | 45 |
| 124 | Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. <i>European Urology</i> , 2009 , 56, 134-40 | 10.2 | 44 |
| 123 | The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. <i>European Urology</i> , 2005 , 48, 162-7 | 10.2 | 43 |
| 122 | Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. <i>European Urology</i> , 2013 , 64, 610-21 | 10.2 | 41 |
| 121 | Intravesical resiniferatoxin desensitizes rat bladder sensory fibres without causing intense noxious excitation. A c-fos study. <i>European Journal of Pharmacology</i> , 1999 , 378, 17-22 | 5.3 | 41 |
| 120 | Insulin induces cobalt uptake in a subpopulation of rat cultured primary sensory neurons. <i>European Journal of Neuroscience</i> , 2003 , 18, 2477-86 | 3.5 | 40 |
| 119 | Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?. <i>Current Opinion in Urology</i> , 2014 , 24, 21-8 | 2.8 | 39 |
| 118 | Activation of the c-fos proto-oncogene in the spinal cord following noxious stimulation of the urinary bladder. <i>Somatosensory & Motor Research</i> , 1994 , 11, 319-25 | 1.2 | 38 |
| 117 | Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. <i>Urology</i> , 2014 , 83, 1030-4 | 1.6 | 36 |
| 116 | Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). <i>Neurourology and Urodynamics</i> , 2014 , 33 Suppl 3, S26-31 | 2.3 | 32 |
| 115 | Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. <i>World Journal of Urology</i> , 2014 , 32, 1119-25 | 4 | 32 |
| 114 | Short-term assessment of a tension-free vaginal tape for treating female stress urinary incontinence. <i>BJU International</i> , 2009 , 104, 225-8 | 5.6 | 32 |
| 113 | Neurochemical characterization of insulin receptor-expressing primary sensory neurons in wild-type and vanilloid type 1 transient receptor potential receptor knockout mice. <i>Journal of Comparative Neurology</i> , 2007 , 503, 334-47 | 3.4 | 32 |
| 112 | The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO). <i>Journal of Neuroscience</i> , 2015 , 35, 2146-60 | 6.6 | 30 |
| 111 | Bladder sensory desensitization decreases urinary urgency. <i>BMC Urology</i> , 2007 , 7, 9 | 2.2 | 29 |
| 110 | Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. <i>European Urology</i> , 2004 , 46, 88-93; discussion 93-4 | 10.2 | 29 |

| | | | |
|-----|--|------|----|
| 109 | Intratrigenal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial. <i>Journal of Urology</i> , 2018 , 199, 998-1003 | 2.5 | 28 |
| 108 | Lower Urinary Tract Symptoms and Aging: The Impact of Chronic Bladder Ischemia on Overactive Bladder Syndrome. <i>Urologia Internationalis</i> , 2015 , 95, 373-9 | 1.9 | 28 |
| 107 | Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. <i>BMC Urology</i> , 2009 , 9, 9 | 2.2 | 27 |
| 106 | Desensitization follows excitation of bladder primary afferents by intravesical capsaicin, as shown by c-fos activation in the rat spinal cord. <i>Pain</i> , 1996 , 64, 553-557 | 8 | 27 |
| 105 | Biomarkers of spinal cord injury and ensuing bladder dysfunction. <i>Advanced Drug Delivery Reviews</i> , 2015 , 82-83, 153-9 | 18.5 | 26 |
| 104 | Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012 , 166, 35-8 | 2.4 | 26 |
| 103 | Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. <i>Experimental Neurology</i> , 2008 , 214, 301-8 | 5.7 | 26 |
| 102 | The activation of the ERK pathway contributes to the spinal c-fos expression observed after noxious bladder stimulation. <i>Somatosensory & Motor Research</i> , 2007 , 24, 15-20 | 1.2 | 26 |
| 101 | Characterization of VEGF and angiopoietins expression in human corpus cavernosum during aging. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1410-8 | 1.1 | 25 |
| 100 | Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. <i>Neurourology and Urodynamics</i> , 2017 , 36, 1972-1980 | 2.3 | 24 |
| 99 | Effect of onabotulinumtoxinA on intramural parasympathetic ganglia: an experimental study in the guinea pig bladder. <i>Journal of Urology</i> , 2012 , 187, 1121-6 | 2.5 | 24 |
| 98 | A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. <i>Thyroid</i> , 2017 , 27, 1058-1067 | 6.2 | 23 |
| 97 | Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2085-96 | 4 | 23 |
| 96 | Treatment of male stress urinary incontinence with the adjustable transobturator male system: Outcomes of a multi-center Iberian study. <i>Neurourology and Urodynamics</i> , 2018 , 37, 1458-1466 | 2.3 | 22 |
| 95 | Lidocaine prevents noxious excitation of bladder afferents induced by intravesical capsaicin without interfering with the ensuing sensory desensitization: an experimental study in the rat. <i>Journal of Urology</i> , 1998 , 159, 567-70 | 2.5 | 22 |
| 94 | Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. <i>Experimental Neurology</i> , 2006 , 200, 66-73 | 5.7 | 22 |
| 93 | Nerve growth factor regulates galanin and c-jun overexpression occurring in dorsal root ganglion cells after intravesical resiniferatoxin application. <i>Brain Research</i> , 2002 , 951, 264-9 | 3.7 | 22 |
| 92 | Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. <i>Neurourology and Urodynamics</i> , 2015 , 34, 489-96 | 2.3 | 21 |

| | | | |
|----|---|------|----|
| 91 | Surveillance and management of urologic complications after spinal cord injury. <i>World Journal of Urology</i> , 2018 , 36, 1545-1553 | 4 | 21 |
| 90 | Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019. <i>European Urology Focus</i> , 2019 , 5, 329-336 | 5.1 | 20 |
| 89 | Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. <i>BJU International</i> , 2012 , 110, E422-8 | 5.6 | 20 |
| 88 | VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCG. <i>BMC Physiology</i> , 2011 , 11, 16 | 0 | 20 |
| 87 | Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update. <i>Current Opinion in Urology</i> , 2004 , 14, 329-34 | 2.8 | 20 |
| 86 | Immunocytochemical staining of neuropeptides in terminal arborization of primary afferent fibers anterogradely labeled and identified at light and electron microscopic levels. <i>Journal of Neuroscience Methods</i> , 1992 , 42, 105-13 | 3 | 20 |
| 85 | Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. <i>European Urology</i> , 2020 , 77, 119-128 | 10.2 | 20 |
| 84 | Biomarkers in lower urinary tract symptoms/overactive bladder: a critical overview. <i>Current Opinion in Urology</i> , 2014 , 24, 352-7 | 2.8 | 19 |
| 83 | Single-incision sling system as primary treatment of female stress urinary incontinence: prospective 12 months data from a single institution. <i>BJU International</i> , 2011 , 108, 1616-21 | 5.6 | 19 |
| 82 | Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats. <i>Experimental Neurology</i> , 2016 , 285, 159-166 | 5.7 | 17 |
| 81 | Botulinum toxin treatment for bladder dysfunction. <i>International Journal of Urology</i> , 2013 , 20, 956-62 | 2.3 | 17 |
| 80 | Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. <i>BJU International</i> , 2011 , 107, 1950-4 | 5.6 | 17 |
| 79 | Are all metabolic syndrome components responsible for penile hemodynamics impairment in patients with erectile dysfunction? The role of body fat mass assessment. <i>Journal of Sexual Medicine</i> , 2011 , 8, 831-9 | 1.1 | 17 |
| 78 | An integrated program of extracorporeal membrane oxygenation (ECMO) assisted cardiopulmonary resuscitation and uncontrolled donation after circulatory determination of death in refractory cardiac arrest. <i>Resuscitation</i> , 2018 , 133, 88-94 | 4 | 17 |
| 77 | The water avoidance stress induces bladder pain due to a prolonged alpha1A adrenoceptor stimulation. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , 2017 , 390, 839-844 | 3.4 | 16 |
| 76 | Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. <i>BJU International</i> , 2015 , 115, 452-60 | 5.6 | 16 |
| 75 | N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. <i>Neuropharmacology</i> , 2009 , 56, 676-83 | 5.5 | 16 |
| 74 | Cystitis is associated with TRPV1b-downregulation in rat dorsal root ganglia. <i>NeuroReport</i> , 2008 , 19, 1469-72 | 1.7 | 16 |

| | | | |
|----|--|-----|----|
| 73 | Management of Female and Functional Urology Patients During the COVID Pandemic. <i>European Urology Focus</i> , 2020 , 6, 1049-1057 | 5.1 | 14 |
| 72 | Adjustable Transobturator Male System after Failed Surgical Devices for Male Stress Urinary Incontinence: A Feasibility Study. <i>Urologia Internationalis</i> , 2018 , 101, 106-113 | 1.9 | 14 |
| 71 | Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. <i>Current Opinion in Urology</i> , 2009 , 19, 347-52 | 2.8 | 13 |
| 70 | Unilateral adrenal hyperplasia. <i>Southern Medical Journal</i> , 1994 , 87, 664-7 | 0.6 | 13 |
| 69 | Neurotrophins in the lower urinary tract: becoming of age. <i>Current Neuropharmacology</i> , 2011 , 9, 553-8 | 7.6 | 12 |
| 68 | Patient satisfaction with adjustable transobturator male system in the Iberian multicenter study. <i>World Journal of Urology</i> , 2019 , 37, 2189-2197 | 4 | 12 |
| 67 | Evidence for an urethro-vesical crosstalk mediated by serotonin. <i>Neurourology and Urodynamics</i> , 2018 , 37, 2389-2397 | 2.3 | 11 |
| 66 | Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). <i>International Journal of Urology</i> , 2016 , 23, 572-9 | 2.3 | 11 |
| 65 | From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. <i>International Journal of Women's Health</i> , 2015 , 7, 735-44 | 2.8 | 11 |
| 64 | Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection. <i>BMC Urology</i> , 2012 , 12, 1 | 2.2 | 11 |
| 63 | Recurrent Urinary Tract Infections: Uro-Vaxom [®] , a New Alternative. <i>European Urology Supplements</i> , 2009 , 8, 762-768 | 0.9 | 11 |
| 62 | α-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?. <i>Advances in Therapy</i> , 2017 , 33, 2110-2121 | 4.1 | 10 |
| 61 | The medical treatment of overactive bladder, including current and future treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1041-55 | 4 | 10 |
| 60 | Does baseline total testosterone improve the yielding of prostate cancer screening?. <i>European Journal of Cancer</i> , 2012 , 48, 1657-63 | 7.5 | 9 |
| 59 | Sites of renal pain processing in the rat spinal cord. A c-fos study using a percutaneous method to perform ureteral obstruction. <i>Journal of the Autonomic Nervous System</i> , 1997 , 67, 60-6 | | 9 |
| 58 | Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. <i>Handbook of Experimental Pharmacology</i> , 2011 , 345-74 | 3.2 | 9 |
| 57 | Pathophysiological mechanisms in detrusor underactivity: Novel experimental findings. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, 92-98 | 1.9 | 8 |
| 56 | New Concepts and Pathophysiology of Lower Urinary Tract Symptoms in Men. <i>European Urology Supplements</i> , 2010 , 9, 472-476 | 0.9 | 8 |

| | | | |
|----|---|-----|---|
| 55 | Use of botulinum toxin for genitourinary conditions: What is the evidence?. <i>Toxicon</i> , 2015 , 107, 141-7 | 2.8 | 7 |
| 54 | Long-term outcome of adjustable transobturator male system for stress urinary incontinence in the Iberian multicentre study. <i>Neurourology and Urodynamics</i> , 2020 , 39, 1737-1745 | 2.3 | 7 |
| 53 | Sympathetic nervous system and chronic bladder pain: a new tune for an old song. <i>Translational Andrology and Urology</i> , 2015 , 4, 534-42 | 2.3 | 7 |
| 52 | The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. <i>Journal of Urology</i> , 2002 , 575-579 | 3.5 | 7 |
| 51 | The Impact of Chronic Pelvic Ischemia on LUTS and Urinary Levels of Neuroinflammatory, Inflammatory, and Oxidative Stress Markers in Elderly Men: A Case-control Study. <i>Urology</i> , 2019 , 123, 230-234 | 1.6 | 7 |
| 50 | Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxin A or abobotulinumtoxin A: A comparative study in the mice. <i>Neurourology and Urodynamics</i> , 2017 , 36, 86-90 | 2.3 | 6 |
| 49 | Underactive bladder in aging rats is associated with a reduced number of serotonin-expressing cells in the urethra and is improved by serotonin application to the urethra. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, 248-254 | 1.9 | 6 |
| 48 | Effects of early intravesical administration of resiniferatoxin to spinal cord-injured rats in neurogenic detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2019 , 38, 1540-1550 | 2.3 | 5 |
| 47 | Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure. <i>Urology</i> , 2017 , 99, 49-56 | 1.6 | 5 |
| 46 | Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?. <i>European Journal of Cancer Prevention</i> , 2014 , 23, 166-72 | 2 | 5 |
| 45 | Overactive bladder: pathophysiology, diagnostics, and therapies. <i>Advances in Urology</i> , 2011 , 2011, 8635046 | 4.6 | 5 |
| 44 | Vascular endothelial growth factor (VEGF) and prostate pathology. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010 , 36, 430-7; discussion 438 | 2 | 5 |
| 43 | Renal Cell Carcinoma with Venous Thrombus: Should Surgery Be Offered When Metastasis Is Present at Diagnosis?. <i>Urologia Internationalis</i> , 2018 , 101, 387-390 | 1.9 | 5 |
| 42 | Effect of Water Avoidance Stress on serum and urinary NGF levels in rats: diagnostic and therapeutic implications for BPS/IC patients. <i>Scientific Reports</i> , 2019 , 9, 14113 | 4.9 | 4 |
| 41 | Intrarenal artery pseudoaneurysm after blunt abdominal trauma: a case report of successful superselective angioembolization. <i>Research and Reports in Urology</i> , 2014 , 6, 17-20 | 1.3 | 4 |
| 40 | Mini-arc for the treatment of female stress urinary incontinence: long-term prospective evaluation by patient reported outcomes. <i>ISRN Urology</i> , 2014 , 2014, 659383 | | 4 |
| 39 | Artificial urinary sphincter or a second adjustable transobturator male system: better equivalent outcomes in patients whom required revision on the initial ATOMS device: An international multi-institutional experience. <i>Neurourology and Urodynamics</i> , 2021 , 40, 897-909 | 2.3 | 4 |
| 38 | Cohort Profile: The Maule Cohort (MAUCO). <i>International Journal of Epidemiology</i> , 2020 , 49, 760-761 | 7.8 | 3 |

| | | | |
|----|--|------|---|
| 37 | Acute transient myopia with shallowing of the anterior chamber induced by sulfamethoxazole in a patient with pseudoxanthoma elasticum. <i>Journal of Glaucoma</i> , 2014 , 23, 415-7 | 2.1 | 3 |
| 36 | Open to debate. The Motion: antimuscarinics are the mainstay of therapy for overactive bladder. <i>European Urology</i> , 2008 , 54, 226-30 | 10.2 | 3 |
| 35 | Treatment of priapism. <i>Lancet, The</i> , 1984 , 2, 1348 | 40 | 3 |
| 34 | Position of the Ibero-American Society of Neurourology and Urogynecology in relation to the use of synthetic suburethral meshes for the surgical treatment of female stress incontinence. <i>Neurourology and Urodynamics</i> , 2020 , 39, 464-469 | 2.3 | 3 |
| 33 | Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020 , 393, 263-272 | 3.4 | 3 |
| 32 | Current pharmacotherapy of overactive bladder. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021 , 47, 1091-1107 | 2 | 3 |
| 31 | Position of Ibero-American Society of Neurourology and UroGynecology (SINUG) on the use of vaginal meshes in pelvic organ prolapse. <i>Neurourology and Urodynamics</i> , 2020 , 39, 1020-1025 | 2.3 | 2 |
| 30 | TRPV1 in Visceral Pain and Other Visceral Disorders 206-238 | | 2 |
| 29 | A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. <i>Thyroid</i> , 2020 , 30, 704-712 | 6.2 | 2 |
| 28 | Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain. <i>Pain</i> , 2021 , 162, 2349-2365 | 8 | 2 |
| 27 | Adjustable Transobturator Male System (ATOMS) Infection: Causative Organisms and Clinical Profile. <i>Urology</i> , 2021 , | 1.6 | 2 |
| 26 | Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).. <i>European Urology</i> , 2022 , | 10.2 | 2 |
| 25 | Pharmacology of the lower urinary tract: update on LUTS treatment. <i>Therapeutic Advances in Urology</i> , 2020 , 12, 1756287220922425 | 3.2 | 1 |
| 24 | Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019. <i>Current Opinion in Urology</i> , 2020 , 30, 486-490 | 2.8 | 1 |
| 23 | Evaluation of the Donor After Brain Death and Technique for Organ Procurement. <i>European Urology Supplements</i> , 2016 , 15, 390-396 | 0.9 | 1 |
| 22 | Intravesical strategies to manage the neurogenic bladder. <i>Current Bladder Dysfunction Reports</i> , 2008 , 3, 133-139 | 0.4 | 1 |
| 21 | Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. <i>European Urology Focus</i> , 2016 , 2, 329-331 | 5.1 | 1 |
| 20 | Mini-Slings: Do They Stand the Test of Time? A 10-Year Cohort. <i>Urologia Internationalis</i> , 2021 , 105, 143-147 | | 1 |

| | | | |
|----|--|------|---|
| 19 | Treatment of Non-neurogenic Lower Urinary Tract Symptoms-A Review of Key Publications from 2018 Onward. <i>European Urology Focus</i> , 2021 , 7, 1438-1447 | 5.1 | o |
| 18 | DU Is Induced by Low Levels of Urinary ATP in a Rat Model of Partial Bladder Outlet Obstruction: The Incidence of Both Events Decreases after Deobstruction.. <i>Advances in Urology</i> , 2022 , 2022, 6292457 | 1.6 | o |
| 17 | The Role of Urinary VEGF in Observational Studies of BPS/IC Patients: A Systematic Review. <i>Diagnostics</i> , 2022 , 12, 1037 | 3.8 | o |
| 16 | Author Reply. <i>Urology</i> , 2017 , 99, 55-56 | 1.6 | |
| 15 | Botulinum Toxin Injections in the Bladder and Urethral Sphincter 2019 , 291-298 | | |
| 14 | Intravesical Capsaicin and Resiniferatoxin for Bladder Disorders 2015 , 119-127 | | |
| 13 | Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). <i>European Urology</i> , 2015 , 67, 1189-90 | 10.2 | |
| 12 | Single Incision Slings: Is There a Role?. <i>Current Bladder Dysfunction Reports</i> , 2013 , 8, 19-24 | 0.4 | |
| 11 | TRP Channels in the Genitourinary Tract. <i>Methods in Pharmacology and Toxicology</i> , 2012 , 373-395 | 1.1 | |
| 10 | Reply to Tomasz Drewa, Zbigniew Wolski and Janusz Tyloch. Letter to the Editor re: Joāo Silva, Rui Pinto, Tiago Carvallho, et al. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. <i>Eur Urol</i> 2009;56:134-141. <i>European Urology</i> , 2009 , 56, e28-e29 | 10.2 | |
| 9 | Editorial comment on: Effect of thalamic deep brain stimulation on lower urinary tract function. <i>European Urology</i> , 2008 , 53, 612 | 10.2 | |
| 8 | Re: Liu L, Mansfield KJ, Kristiana I, et al. 2007. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. <i>Neurourol Urodynam</i> 26:433-438. <i>Neurourology and Urodynamics</i> , 2007 , 26, 439-439 | 2.3 | |
| 7 | Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients.. <i>Turkish Journal of Urology</i> , 2022 , 48, 82-87 | 1.3 | |
| 6 | TRPV1 agonist therapies in bladder diseases 2005 , 211-225 | | |
| 5 | Editorial Comment. <i>Journal of Urology</i> , 2020 , 204, 323 | 2.5 | |
| 4 | Kidney transplantation from donation after circulatory death using abdominal normothermic oxygenated circulation: are the outcomes equivalent?. <i>International Urology and Nephrology</i> , 2021 , 53, 1355-1359 | 2.3 | |
| 3 | Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). <i>European Urology</i> , 2016 , 70, 892 | 10.2 | |
| 2 | Re: European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2021 , 79, 427 | 10.2 | |

- 1 Minimally Invasive Treatments **2018**, 387-404